Ashleigh Furlong
Health Reporter at Bloomberg News
Health reporter @bloomberg. Previously @POLITICOEurope, @ResFortnight and @GroundUp_News. Views my own. Send tips to [email protected] or DM me.
Articles
-
3 weeks ago |
seattletimes.com | Ashleigh Furlong
Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye condition that can cause vision loss, according to Europe’s drug regulator. The European Medicines Agency’s safety committee found that an eye condition called NAION is a “very rare” side effect of semaglutide, a key ingredient in diabetes and obesity drugs.
-
3 weeks ago |
bloomberg.com | Ashleigh Furlong
Ozempic injection pens. (Bloomberg) -- Patients taking weight-loss medicines such as Novo Nordisk A/S’s Ozempic and Wegovy are at risk of developing an eye condition that can cause vision loss, according to Europe’s drug regulator. The European Medicines Agency’s safety committee found that an eye condition called NAION is a “very rare” side effect of semaglutide, a key ingredient in diabetes and obesity drugs.
-
3 weeks ago |
bloomberg.com | Ashleigh Furlong
Hello, it’s Ashleigh in London, where I’ve been looking into the intersection of two big hot topics – women’s health and the microbiome. But before we get into that…Help us improve Bloomberg newsletters: Please take a quick survey to share your thoughts on your sign-up experience and what you’d like to see in the future.
-
3 weeks ago |
news.bloomberglaw.com | Phoebe Sedgman |Amber Tong |Ashleigh Furlong
Sanofi agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the French drugmaker expands further in rare immunological diseases. Sanofi will pay $129 per share in cash for the US biotech, it said in a statement. That represents a 27% premium to Blueprint’s closing price on Friday. The pharmaceutical firm has touted its ambition to become an immunology powerhouse, and earlier this year it clinched a pact to buy a promising antibody drug for up to $1.9 billion.
-
3 weeks ago |
bloomberglinea.com.br | Phoebe Sedgman |Amber Tong |Ashleigh Furlong |Seong Joon Cho
Bloomberg — A Sanofi concordou em comprar a Blueprint por pelo menos US$ 9,1 bilhões, à medida que a farmacêutica francesa se expande ainda mais em doenças imunológicas raras. A Sanofi pagará US$ 129 por ação pela biotecnologia americana, informou em um comunicado. Isso representa um prêmio de 27% sobre o preço de fechamento da Blueprint na sexta-feira.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 4K
- Tweets
- 3K
- DMs Open
- Yes
RT @WHO: Current Heads of WHO Collaborating Centres back the Organization in a new open letter in The Lancet. https://t.co/nmOy3W0QzB
RT @AmberTongPW: Sanofi to Buy Immunology Biotech Blueprint for $9.1 Billion (while Blueprint was once focused on precision cancer therapi…
RT @RWB_Mills: It’s free (up to 30 scans p/m) and totally anonymous. This tool is still very much in early stages, with some bugs – but any…